Floatz logo

Vibostolimab

Metastatic Neoplasm

Merck Sharp & Dohme LLCmonoclonal_antibodyPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

170 Active assets in the Metastatic Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Eloxatin
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Ipilimumab
7 Hills Pharma, LLC
Phase 3BB

View all 50 →

Same molecule, other indications

Vibostolimab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
melanomaDormant
B
Indicative ·
59 / 100
View asset →
lung neoplasmDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →